OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
This collaboration is part of GSK’s “Discovery Partnerships with Academia” (DPAc) efforts.
Networking, lab tours highlight first OMRF BioVenture Forum
OMRF’s Charles Esmon was recognized by the AHA as a distinguished scientist.
Trauma is a leading cause of death in people under age 34.
New research reveals a protein studied at OMRF plays a role in malarial stroke.